IRIS
PORTA, Camillo Guglielmo Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.411
AS - Asia 5.731
EU - Europa 5.123
SA - Sud America 2.318
AF - Africa 263
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 21.859
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.112
IT - Italia 2.276
SG - Singapore 2.243
BR - Brasile 1.788
HK - Hong Kong 859
CN - Cina 701
VN - Vietnam 685
FR - Francia 494
RU - Federazione Russa 445
SE - Svezia 432
FI - Finlandia 415
DE - Germania 346
GB - Regno Unito 253
ID - Indonesia 231
AR - Argentina 200
BD - Bangladesh 192
IN - India 161
CA - Canada 124
EC - Ecuador 99
IQ - Iraq 93
TR - Turchia 85
MX - Messico 75
AT - Austria 74
CO - Colombia 73
JP - Giappone 73
ZA - Sudafrica 69
NL - Olanda 68
PK - Pakistan 67
ES - Italia 57
SA - Arabia Saudita 53
IE - Irlanda 48
PH - Filippine 48
CI - Costa d'Avorio 47
VE - Venezuela 47
MA - Marocco 41
UZ - Uzbekistan 38
PL - Polonia 37
PY - Paraguay 37
CL - Cile 29
JM - Giamaica 22
JO - Giordania 21
KE - Kenya 20
UA - Ucraina 20
AZ - Azerbaigian 19
AL - Albania 18
BE - Belgio 18
EG - Egitto 18
NP - Nepal 18
MY - Malesia 17
PE - Perù 17
TN - Tunisia 16
LT - Lituania 15
AE - Emirati Arabi Uniti 13
CZ - Repubblica Ceca 13
UY - Uruguay 13
DO - Repubblica Dominicana 12
BO - Bolivia 11
HN - Honduras 11
ET - Etiopia 10
GT - Guatemala 10
IL - Israele 10
RO - Romania 10
CH - Svizzera 9
CR - Costa Rica 9
OM - Oman 9
PT - Portogallo 9
TH - Thailandia 9
AU - Australia 8
BH - Bahrain 8
DZ - Algeria 8
KR - Corea 8
KZ - Kazakistan 8
RS - Serbia 8
MK - Macedonia 7
PS - Palestinian Territory 7
BG - Bulgaria 6
KG - Kirghizistan 6
LB - Libano 6
NI - Nicaragua 6
PR - Porto Rico 6
QA - Qatar 6
SN - Senegal 6
SY - Repubblica araba siriana 6
TT - Trinidad e Tobago 6
AO - Angola 5
PA - Panama 5
TW - Taiwan 5
AM - Armenia 4
BB - Barbados 4
BY - Bielorussia 4
DK - Danimarca 4
HR - Croazia 4
HU - Ungheria 4
LU - Lussemburgo 4
BA - Bosnia-Erzegovina 3
DM - Dominica 3
GE - Georgia 3
KH - Cambogia 3
LV - Lettonia 3
MD - Moldavia 3
Totale 21.789
Salva come PNG Salva come JPEG
Città #
Singapore 1.188
Ashburn 1.036
Hong Kong 841
Milan 837
Fairfield 648
San Jose 637
Helsinki 400
Cambridge 347
Nyköping 338
Rome 302
Lauterbourg 275
Woodbridge 265
Houston 260
Seattle 258
Bari 249
Council Bluffs 246
Wilmington 227
Dallas 226
Chandler 223
Lawrence 221
Ho Chi Minh City 211
New York 202
Roxbury 202
Jakarta 178
Los Angeles 162
Beijing 150
São Paulo 142
Paris 140
Hanoi 127
Falkenstein 122
Chicago 121
Des Moines 121
Santa Clara 121
Columbus 114
Ann Arbor 112
Dong Ket 111
Boardman 96
Buffalo 92
San Diego 86
Inglewood 75
Nuremberg 73
London 72
Figino 68
Salt Lake City 65
Rio de Janeiro 55
Frankfurt am Main 50
Abidjan 47
Dublin 47
Turin 47
Belo Horizonte 41
Tokyo 41
Brooklyn 40
Munich 39
Guayaquil 36
Johannesburg 36
Montreal 34
Vienna 34
Baghdad 33
Naples 33
Tashkent 33
Curitiba 30
Manchester 28
Phoenix 28
Porto Alegre 28
Quito 28
Toronto 28
Da Nang 27
Medellín 27
Salvador 27
Warsaw 27
Haiphong 26
Istanbul 25
Orem 25
Atlanta 24
Elk Grove Village 24
Brasília 22
Buenos Aires 22
Jeddah 22
Lahore 22
Caracas 21
Chennai 21
Dhaka 21
Mexico City 21
San Francisco 21
Campinas 20
Denver 19
Guarulhos 19
Amman 18
Amsterdam 18
Asunción 18
Goiânia 18
Moscow 18
Princeton 18
Bogotá 17
Florence 17
Baku 16
Bologna 16
Kingston 16
Miami 16
Nairobi 16
Totale 13.508
Salva come PNG Salva come JPEG
Nome #
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study 249
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation 171
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 170
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM) 154
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 151
An update on Merkel cell carcinoma 146
The clonal heterogenicity of circulating tumor cells (CTCs) drives their metastatic potential: a new NOD‐SCID melanoma model 142
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial 141
The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice 141
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 136
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer 133
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification 131
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma 130
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 127
Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes 126
Integration of lipidomics and transcriptomics reveals reprogramming of the lipid metabolism and composition in clear cell renal cell carcinoma 126
Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma 126
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 125
Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review 125
Large extracellular vesicles—a new frontier of liquid biopsy in oncology 124
Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer 123
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial 122
Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 121
Massive hyper-progression during anti-PD1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review 120
Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art 119
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma 119
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial 118
Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies 116
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma 115
Prognostic factors and current treatment strategies for renal cell carcinoma metastatic to the brain: An overview 114
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 114
An anti-mica/b antibody and il-15 rescue altered nkg2d-dependent nk cell responses in hepatocellular carcinoma 113
1101MO Development of CAR T-cells for future treatment of NETs 112
Exploring the Spectrum of Kidney Ciliopathies 110
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas 107
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy 106
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 105
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 103
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale 102
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 100
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 100
Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases 100
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 99
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 98
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 98
Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors 98
Non-Melanoma Skin Cancers: Biological and Clinical Features 97
Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma 96
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma 96
Hormone signaling pathways as treatment targets in renal cell cancer (Review) 96
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer 96
Primary soft tissue sarcoma of the heart: An emerging chapter in cardio-oncology 95
Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model. 95
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? 94
Beyond ras and braf: Her2, a new actionable oncotarget in advanced colorectal cancer 94
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 93
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists 93
Acute Kidney Injury in Cancer Patients 93
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés 92
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis 92
Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer 92
Liquid biopsy in cervical cancer: Hopes and pitfalls 92
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study 91
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 91
Understanding the mechanisms of resistance in EGFR-positive NSCLC: From tissue to liquid biopsy to guide treatment strategy 90
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 90
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival 90
[Current approaches to the first-line treatment of clear-cell renal cell carcinoma] 89
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study 89
Adjuvant therapy in renal cell carcinoma 88
A Glimpse in the Future of Malignant Mesothelioma Treatment 88
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma 88
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus 88
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations 87
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study 87
Choosing the right cell line for renal cell cancer research 87
Opening an onconephrology clinic: Recommendations and basic requirements 87
Uterine carcinosarcoma: An overview 87
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis 86
Abstract 2012: In vitro validation of tumor-derived large extracellular vesicles isolation and characterization as suitable tool for liquid biopsy 85
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma 85
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 85
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer 84
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 84
Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial 83
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial 83
The emerging role of PI3K inhibitors for solid tumour treatment and beyond 82
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 82
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 82
Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells 81
Onco-nephrology: A decalogue 81
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: Results of the DATECAN project 81
An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy 81
Playing the devil’s advocate: Should we give a second chance to mTOR inhibition in renal clear cell carcinoma? – ie strategies to revert resistance to mtor inhibitors 81
MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management 80
Abstract 2808: Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model 80
Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma 80
Melanoma Brain Metastases: A Retrospective Analysis of Prognostic Factors and Efficacy of Multimodal Therapies 80
The role of the cell-cell interactions in cancer progression 79
Abemaciclib for malignant pleural mesothelioma 78
Totale 10.452
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.903
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.903
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.514 273 22 10 16 66 162 24 40 150 148 226 377
2022/20231.206 236 152 137 22 73 139 138 77 151 10 20 51
2023/2024716 46 240 48 40 54 110 22 39 38 11 13 55
2024/20254.713 207 27 493 256 83 331 473 235 259 370 730 1.249
2025/202612.138 1.294 467 832 1.437 815 622 1.247 611 1.446 1.206 472 1.689
2026/2027560 560 0 0 0 0 0 0 0 0 0 0 0
Totale 23.440